The role of radiotherapy in patients with advanced melanoma failing targeted therapy
DOI:
https://doi.org/10.2340/ao.v65.45437Keywords:
Melanoma, Radiotherapy, Molecular Targeted Therapy, Drug resistance, Proto-oncogene proteins B-rafAbstract
Background and purpose: Approximately 50% of patients with metastatic melanoma harbor mutations in the BRAF gene, making them eligible for targeted therapy (TT). However, treatment options become limited once resistance develops. The role of radiotherapy (RT) in this context remains uncertain, and concerns exist regarding toxicity when RT is delivered concurrently with TT.
Patient/material and methods: This retrospective study included metastatic melanoma patients treated with RT after experiencing disease progressing on TT between 2015 and 2023. Patients were grouped by subsequent systemic therapy: RT-STOP (discontinued TT), RT-TT (continued TT), and RT-ICI (switched to immune checkpoint inhibitors (ICI)). Study endpoints were progression-free survival (PFS), overall survival (OS), efficacy, and toxicity.
Results: Sixty-three patients were analyzed. Median PFS and OS were 1.9 and 3.1 months. The median OS in RT-STOP, RT-TT, and RT-ICI was 1.7, 4.7, and 3.0 months, while the 1-year OS rate was 4.9, 7.6, and 33.4%, respectively (p = 0.001). RT was well tolerated, with no grade ≥3 adverse events observed and 50.9% of patients derived a local benefit.
Interpretation: In advanced melanoma patients with disease progression on TT, RT was safe and provided a local effect. Although survival outcomes remained suboptimal, continuation of TT beyond progression or transition to ICI following RT was associated with improved OS compared with discontinuation of TT. These results support the role of RT as a safe bridging modality, suggest benefit from treatment beyond progression with TT, and warrant confirmation in prospective trials.
Downloads
References
Ottaviano M, Giunta EF, Tortora M, Curvietto M, Attademo L, Bosso D, et al. BRAF gene and melanoma: back to the future. Int J Mol Sci. 2021;22(7):3474.
https://doi.org/10.3390/ijms22073474 DOI: https://doi.org/10.3390/ijms22073474
Bauer J, Buttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011;24(2):345–51.
https://doi.org/10.1111/j.1755-148X.2011.00837.x DOI: https://doi.org/10.1111/j.1755-148X.2011.00837.x
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.
https://doi.org/10.1056/NEJMoa1103782 DOI: https://doi.org/10.1056/NEJMoa1103782
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.
https://doi.org/10.1056/NEJMoa1203421 DOI: https://doi.org/10.1056/NEJMoa1203421
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88.
https://doi.org/10.1056/NEJMoa1406037 DOI: https://doi.org/10.1056/NEJMoa1406037
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.
https://doi.org/10.1056/NEJMoa1412690 DOI: https://doi.org/10.1056/NEJMoa1412690
Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.
https://doi.org/10.1056/NEJMoa1408868 DOI: https://doi.org/10.1056/NEJMoa1408868
Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, et al. COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. Eur J Cancer. 2024;204:114073.
https://doi.org/10.1016/j.ejca.2024.114073 DOI: https://doi.org/10.1016/j.ejca.2024.114073
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–36.
https://doi.org/10.1056/NEJMoa1904059 DOI: https://doi.org/10.1056/NEJMoa1904059
Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.
https://doi.org/10.1016/S1470-2045(16)30122-X DOI: https://doi.org/10.1016/S1470-2045(16)30122-X
Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186–97.
https://doi.org/10.1200/JCO.22.01763 DOI: https://doi.org/10.1200/JCO.22.01763
Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, et al. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024;15(1):146.
https://doi.org/10.1038/s41467-023-44475-6 DOI: https://doi.org/10.1038/s41467-023-44475-6
Priantti JN, Vilbert M, Madeira T, Moraes FCA, Hein ECK, Saeed A, et al. Efficacy and safety of rechallenge with BRAF/MEK inhibitors in advanced melanoma patients: a systematic review and meta-analysis. Cancers (Basel). 2023;15(15):3754.
https://doi.org/10.3390/cancers15153754 DOI: https://doi.org/10.3390/cancers15153754
Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, et al. Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin Cancer Res. 2020;26(1):46–53.
https://doi.org/10.1158/1078-0432.CCR-18-4180 DOI: https://doi.org/10.1158/1078-0432.CCR-18-4180
Ascierto PA, Mandala M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol. 2023;41(2):212–21.
https://doi.org/10.1200/JCO.21.02961 DOI: https://doi.org/10.1200/JCO.21.02961
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–27.
https://doi.org/10.1016/S1470-2045(18)30497-2 DOI: https://doi.org/10.1016/S1470-2045(18)30497-2
Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol. 2015;26(6):1238–44.
https://doi.org/10.1093/annonc/mdv139 DOI: https://doi.org/10.1093/annonc/mdv139
Peuvrel L, Ruellan AL, Thillays F, Quereux G, Brocard A, Saint-Jean M, et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol. 2013;23(6):879–81.
https://doi.org/10.1684/ejd.2013.2193 DOI: https://doi.org/10.1684/ejd.2013.2193
Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, et al. Vemurafenib and radiosensitization. JAMA Dermatol. 2013;149(7):855–7.
https://doi.org/10.1001/jamadermatol.2013.4200 DOI: https://doi.org/10.1001/jamadermatol.2013.4200
Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol. 2013;31(13):e220–2.
https://doi.org/10.1200/JCO.2012.44.4265 DOI: https://doi.org/10.1200/JCO.2012.44.4265
Palmer JD, Prasad RN, Fabian D, Wei L, Yildiz VO, Tan Y, et al. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiother Oncol. 2022;170:21–6.
https://doi.org/10.1016/j.radonc.2022.03.016 DOI: https://doi.org/10.1016/j.radonc.2022.03.016
Peuvrel L, Dreno B. Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol. 2014;15(5):425–44.
https://doi.org/10.1007/s40257-014-0088-2 DOI: https://doi.org/10.1007/s40257-014-0088-2
Schick U, Kyula J, Barker H, Patel R, Zaidi S, Gregory C, et al. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence. Radiother Oncol. 2015;117(2):364–75.
https://doi.org/10.1016/j.radonc.2015.06.026 DOI: https://doi.org/10.1016/j.radonc.2015.06.026
Márquez-Rodas I, Avilés-Izquierdo JA, Parra V, Álvarez-González A, Borrego P, Fernández-García P, et al. Exclusion criteria vs reality: dual BRAF/MEK inhibition and radiotherapy in a patient with melanoma metastatic to the brain and ECOG 3. Tumori. 2016;102(Suppl. 2):5000408.
https://doi.org/10.5301/tj.5000408 DOI: https://doi.org/10.5301/tj.5000408
Wang W, Smith JL, Carlino MS, Burmeister B, Pinkham MB, Fogarty GB, et al. Phase I/II trial of concurrent extracranial palliative radiation therapy with dabrafenib and trametinib in metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Clin Transl Radiat Oncol. 2021;30:95–9.
https://doi.org/10.1016/j.ctro.2021.08.006 DOI: https://doi.org/10.1016/j.ctro.2021.08.006
Ziegler JS, Kroeze S, Hilbers ML, Imhof L, Guckenberger M, Levesque MP, et al. Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. Melanoma Res. 2020;30(6):552–61.
https://doi.org/10.1097/CMR.0000000000000682 DOI: https://doi.org/10.1097/CMR.0000000000000682
Rossi E, Schinzari G, Cellini F, Balducci M, Pasqualoni M, Maiorano BA, et al. Dabrafenib-trametinib and radiotherapy for oligoprogressive BRAF mutant advanced melanoma. Biomedicines. 2023;11(2):394.
https://doi.org/10.3390/biomedicines11020394 DOI: https://doi.org/10.3390/biomedicines11020394
van Aken ESM, Devnani B, Castelo-Branco L, De Ruysscher D, Martins-Branco D, Marijnen CAM, et al. ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy. Radiother Oncol. 2025;208:110910.
https://doi.org/10.1016/j.radonc.2025.110910 DOI: https://doi.org/10.1016/j.radonc.2025.110910
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66.
https://doi.org/10.1016/j.radonc.2020.04.003 DOI: https://doi.org/10.1016/j.radonc.2020.04.003
Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel F, et al. BRAF/MEK inhibitor rechallenge in advanced melanoma patients. Cancer. 2024;130(9):1673–83.
https://doi.org/10.1002/cncr.35178 DOI: https://doi.org/10.1002/cncr.35178
Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 2017;18(4):464–72.
https://doi.org/10.1016/S1470-2045(17)30171-7 DOI: https://doi.org/10.1016/S1470-2045(17)30171-7
Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, et al. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015;51(11):1435–43.
https://doi.org/10.1016/j.ejca.2015.04.010 DOI: https://doi.org/10.1016/j.ejca.2015.04.010
Backlund E, Grozman V, Egyhazi Brage S, Lewensohn R, Lindberg K, Helgadottir H. Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability. Acta Oncol. 2023;62(12):1921–30.
https://doi.org/10.1080/0284186X.2023.2280766 DOI: https://doi.org/10.1080/0284186X.2023.2280766
Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol. 2011;98(3):394–9.
https://doi.org/10.1016/j.radonc.2010.12.017 DOI: https://doi.org/10.1016/j.radonc.2010.12.017
Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg. 2015;123(2):395–401.
https://doi.org/10.3171/2014.9.JNS141425 DOI: https://doi.org/10.3171/2014.9.JNS141425
Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ, et al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res. 2016;26(4):387–94.
https://doi.org/10.1097/CMR.0000000000000268 DOI: https://doi.org/10.1097/CMR.0000000000000268
Marquez-Rodas I, Alvarez A, Arance A, Valduvieco I, Berciano-Guerrero MA, Delgado R, et al. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study). Neuro Oncol. 2024;26(11):2074–83.
https://doi.org/10.1093/neuonc/noae116 DOI: https://doi.org/10.1093/neuonc/noae116
van Opijnen MP, Dirven L, Coremans IEM, Taphoorn MJB, Kapiteijn EHW. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: a systematic review. Int J Cancer. 2020;146(6):1479–89.
https://doi.org/10.1002/ijc.32696 DOI: https://doi.org/10.1002/ijc.32696
Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018;30(2):125–33.
https://doi.org/10.1097/CCO.0000000000000426 DOI: https://doi.org/10.1097/CCO.0000000000000426
Yilmaz M, Celik U, Hascicek S. Radiation recall dermatitis with dabrafenib and trametinib: a case report. World J Clin Cases. 2020;8(3):522–6.
https://doi.org/10.12998/wjcc.v8.i3.522 DOI: https://doi.org/10.12998/wjcc.v8.i3.522
Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016;95(2):632–46.
https://doi.org/10.1016/j.ijrobp.2016.01.038 DOI: https://doi.org/10.1016/j.ijrobp.2016.01.038
Rogers SJ, Puric E, Eberle B, Datta NR, Bodis SB. Radiotherapy for melanoma: more than DNA damage. Dermatol Res Pract. 2019;2019:9435389.
https://doi.org/10.1155/2019/9435389 DOI: https://doi.org/10.1155/2019/9435389
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Ellen Heurlin, Lina Grödeberg, Hildur Helgadottir
This work is licensed under a Creative Commons Attribution 4.0 International License.
